tetano
Editor, Senior Moderator
Vaccine
Available online 18 October 2012
In Press, Uncorrected Proof ? Note to users
Cover image
Prior infection of chickens with H1N1 avian influenza virus elicits heterologous protection against highly pathogenic H5N2
Charles Nfona,
Yohannes Berhanea, b,
John Pasicka,
Gary Kobingerc, d,
Darwyn Kobasad, e,
Shawn Babiuka, f, Corresponding author contact information, E-mail the corresponding author
a National Centre for Foreign Animal Disease, Canadian Food Inspection Agency, Winnipeg, MB, Canada R3E 3M4
b Department of Animal Science, University of Manitoba, Winnipeg, MB, Canada
c Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canada, Canada
d Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada
e Respiratory Viruses Program, National Microbiology Laboratory, Public Health Agency of Canada, Canada
f Department of Immunology, University of Manitoba, Winnipeg, MB, Canada R3E 0T5
http://dx.doi.org/10.1016/j.vaccine.2012.10.021, How to Cite or Link Using DOI
Abstract
Current vaccines for influenza are primarily killed whole virus vaccines that elicit antibody responses to the homologous virus but lack protection against heterologous viruses. Using chickens as a model we have explored the possibility of using a live low pathogenic avian influenza (LPAI) A/goose/AB/223/2005 H1N1 virus as a vaccine to generate protective immunity against heterologous highly pathogenic avian influenza (HPAI) A/chicken/Pensylvania/1370/1983 H5N2 virus challenge. Virus replicated in chickens infected with LPAI H1N1 but did not cause clinical disease. In addition, these chickens developed neutralizing antibodies to LPAI H1N1 virus, but not HPAI H5N2, 21 days post infection (DPI). Furthermore, peripheral blood mononuclear cells from H1N1-infected chickens at 20 DPI had antigen specific proliferation and IFN-γ secretion following antigen stimulation to H5N2 indicating a heterologous HPAI H5N2 specific cell mediated immunity (CMI) following LPAI H1N1 infection. Following challenge with HPAI H5N2 virus, all control chickens developed clinical disease, while chickens previously infected with H1N1 did not develop clinical disease and shed significantly less virus by oral and cloacal routes. These results indicated that previous infection with LPAI virus can generate heterologous CMI capable of protecting against HPAI H5N2.
Highlights
► Virus replicated in chickens infected with LPAI H1N1 but did not cause clinical disease. ► Chickens developed cross reactive cellular immunity to H5N2. ► Chickens previously infected with H1N1 did not develop clinical disease following H5N2 challenge. ► Protection was observed in the absence of H5 specific antibodies.
http://www.sciencedirect.com/science/article/pii/S0264410X12014673
Available online 18 October 2012
In Press, Uncorrected Proof ? Note to users
Cover image
Prior infection of chickens with H1N1 avian influenza virus elicits heterologous protection against highly pathogenic H5N2
Charles Nfona,
Yohannes Berhanea, b,
John Pasicka,
Gary Kobingerc, d,
Darwyn Kobasad, e,
Shawn Babiuka, f, Corresponding author contact information, E-mail the corresponding author
a National Centre for Foreign Animal Disease, Canadian Food Inspection Agency, Winnipeg, MB, Canada R3E 3M4
b Department of Animal Science, University of Manitoba, Winnipeg, MB, Canada
c Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canada, Canada
d Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada
e Respiratory Viruses Program, National Microbiology Laboratory, Public Health Agency of Canada, Canada
f Department of Immunology, University of Manitoba, Winnipeg, MB, Canada R3E 0T5
http://dx.doi.org/10.1016/j.vaccine.2012.10.021, How to Cite or Link Using DOI
Abstract
Current vaccines for influenza are primarily killed whole virus vaccines that elicit antibody responses to the homologous virus but lack protection against heterologous viruses. Using chickens as a model we have explored the possibility of using a live low pathogenic avian influenza (LPAI) A/goose/AB/223/2005 H1N1 virus as a vaccine to generate protective immunity against heterologous highly pathogenic avian influenza (HPAI) A/chicken/Pensylvania/1370/1983 H5N2 virus challenge. Virus replicated in chickens infected with LPAI H1N1 but did not cause clinical disease. In addition, these chickens developed neutralizing antibodies to LPAI H1N1 virus, but not HPAI H5N2, 21 days post infection (DPI). Furthermore, peripheral blood mononuclear cells from H1N1-infected chickens at 20 DPI had antigen specific proliferation and IFN-γ secretion following antigen stimulation to H5N2 indicating a heterologous HPAI H5N2 specific cell mediated immunity (CMI) following LPAI H1N1 infection. Following challenge with HPAI H5N2 virus, all control chickens developed clinical disease, while chickens previously infected with H1N1 did not develop clinical disease and shed significantly less virus by oral and cloacal routes. These results indicated that previous infection with LPAI virus can generate heterologous CMI capable of protecting against HPAI H5N2.
Highlights
► Virus replicated in chickens infected with LPAI H1N1 but did not cause clinical disease. ► Chickens developed cross reactive cellular immunity to H5N2. ► Chickens previously infected with H1N1 did not develop clinical disease following H5N2 challenge. ► Protection was observed in the absence of H5 specific antibodies.
http://www.sciencedirect.com/science/article/pii/S0264410X12014673